Netflix Inc (NASDAQ:NFLX, ETR:NFC) delivered another blockbuster quarter, beating estimates and raising its full-year outlook, yet its shares fell almost 5% with analysts pointing to sky-high investor expectations as the cause.
Analysts at Bank of America and UBS largely agree on the strength of the streaming giant’s fundamentals, attributing the market’s tepid reaction more to Netflix’s elevated valuation than any shortfall in the results themselves.
Sales of Johnson & Johnson (NYSE:JNJ)’s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for the broader psychedelics sector, according to Jefferies analysts.
Spravato sales grew 29% quarter-over-quarter to $414 million worldwide. US sales grew 33% quarter-over-quarter to $366 million while ex-US sales were up 14% at $50 million.
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares pulled back after Thursday’s gains on the announcement of a third patient death linked to the company’s experimental gene therapies.
The patient, who was participating in a Phase 1 trial for Sarepta’s approved AAVrh74-based gene therapy targeting limb-girdle muscular dystrophy, died from acute liver failure.
The US House of Representatives passed the the GENIUS Act on Thursday evening, the first federal legislation to create a regulatory framework for stablecoins.
Stablecoins are cryptocurrencies tied to stable assets such as the US dollar to maintain a fixed value, designed to function as reliable instruments for payments and financial services.
Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell 6% on Thursday, wiping more than £3bn from its market value, after a US advisory committee delivered a serious blow to the drugmaker’s oncology ambitions.
The Food and Drug Administration’s (FDA) Oncology Drugs Advisory Committee (ODAC) voted against approving GSK’s multiple myeloma drug Blenrep in two separate phase III trials.
Zephyr Energy PLC (AIM:ZPHR, OTCQB:ZPHRF) is making steady progress at its Paradox Basin project in Utah, according to broker Panmure Liberum, but those holding out for clear timelines may have to wait a bit longer.
In a research note, Panmure said the company has begun early work on a gas processing plant and pipeline infrastructure, aiming to unlock value from its State 36-2 well, the centrepiece of its development plans.
GSK PLC (LSE:GSK, NYSE:GSK) shares dropped 6% on Friday, erasing over £3 billion from its market value, after a panel of experts advising the US Food and Drug Administration voted against the company’s Blenrep drug combinations for advanced multiple myeloma.
The advisory committee concluded that the benefits of Blenrep, also known as belantamab mafodotin-blmf, did not outweigh the risks at the proposed dosage used in clinical trials.
Ilika PLC (AIM:IKA, OTCQX:ILIKF) looks to be heading for a turning point. After years of development work, the British battery innovator has started to bring in early commercial revenue and is now lining up what could be a big year in 2026.
A new note from Cavendish highlights how the company’s flagship Goliath solid-state battery technology is gaining traction with the automotive industry.
Netflix Inc (NASDAQ:NFLX, ETR:NFC) is heading into its second quarter earnings report amid a shift in investor sentiment to greater caution as the stock trades near a five-year high, according to analysts at Jefferies.
The analysts remain bullish on the streaming giant, repeating their ‘Buy’ rating and $1,400 price target, which represents upside of 12% from current levels.
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF) rose as much as 15% on Thursday after the neuroscience analytics group said it expects full-year revenues to exceed expectations, supported by strong sales momentum and a clearer path to profitability.
The London-listed company, which provides artificial intelligence-based imaging and biomarker analysis for neurological drug development, said revenue for the year to 30 September will be at least £6.3 million, a 9% rise on the prior year and the highest since it adopted its current commercial strategy.
Meta Platforms Inc (NASDAQ:META, ETR:FB2A, SWX:FB) will soon report its second quarter earnings amid growing optimism from Jefferies analysts, who point to better-than-expected revenue trends, strengthening ad metrics, and continued long-term investments in AI.
The analysts upped their price target to $845 from $790, implying upside of 19% from current levels.
Walt Disney Co (NYSE:DIS, ETR:WDP) is poised to deliver another quarter of strong earnings growth, with UBS analysts expecting to see resilient Parks performance and continued gains in direct-to-consumer (DTC) profitability.
The analysts reiterated their ‘Buy’ rating on the stock and raised their price target to $138 from $120 ahead of the report, representing upside of about 16% from the current share price.
Berenberg says ACG Metals Ltd (LSE:ACG, OTC:ACGAF) is "picking up steam" following a strong first-half operational update, leading to a 17% upgrade in 2025 gold-equivalent production guidance and confirming the company’s expansion remains on schedule.
The broker raised its price target to 820p and reiterated a 'buy' rating.
Canada’s inflation rate ticked up in June, cementing expectations the Bank of Canada will hold interest rates steady at its upcoming July meeting.
June’s Consumer Price Index increased to 1.9% year-over-year, up from 1.7% in May. This was slightly below economists’ expectations of 2%.
NanoViricides (NYSE-A:NNVC) is preparing to launch a Phase 2 clinical trial of its lead antiviral candidate NV-387 for the treatment of Mpox Clade I in the Democratic Republic of Congo (DRC), following ethics approval from the country’s health ministry in May, according to a research note by Zacks Small Cap Research.
The trial will test the efficacy and safety of NV-387, a broad-spectrum antiviral developed using NanoViricides’ proprietary nanomedicine platform, in up to 80 hospitalized patients.
Nvidia Corp (NASDAQ:NVDA, ETR:NVD) shares moved higher after the chipmaker said on Tuesday it expects to resume shipments of its H20 graphics processing units (GPUs) to China shortly, after sales were halted due to US export restrictions.
The company said in a statement that it has filed the required applications with the US government and has received assurances that exports would be approved.
Last week, we reported on the Department of Defense’s $400 million investment in MP Materials, a rare earths producer, and the related off-take agreement designed to secure critical materials for US supply chains.
To get an industry perspective, Proactive spoke with David Merriman, who leads Rare Earth Research at Project Blue, a consultancy focused on this sector.
Ilika PLC's (AIM:IKA, OTCQX:ILIKF) shares rose 7% after the company secured a £1.25 million UK government grant to advance production of its Goliath solid-state batteries for electric vehicles.
The funding is part of the DRIVE35 programme under the Advanced Propulsion Centre’s Demonstrate fund and supports a 12-month project starting in August 2025.
Netflix Inc (NASDAQ:NFLX, ETR:NFC) is set to report strong revenue growth and improved profitability for the second quarter when it hands down its highly anticipated report after markets close on Thursday.
“The fact that Netflix is the first of the major tech names to report earnings also means that this report will generate a lot of attention in the coming days,” XTB research director Kathleen Brooks said.
Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) delivered a solid second quarter of production at its Segilola gold mine in Nigeria and remains on track to meet full-year guidance, with analysts at Hannam & Partners seeing clear near-term upside and a “material re-rating” potential once the company publishes a Pre-Feasibility Study (PFS) for its Douta project in Senegal.
“This is a good set of results and demonstrates a solid operational performance at Segilola,” the analysts wrote in a note following Thor’s release of Q2 production figures.
Peel Hunt has upgraded Accesso Technology Group PLC (LSE:ACSO, OTC:LOQPF) to 'add' from 'hold', arguing that the recent sell-off in the shares has been overdone.
The move comes despite a reduction in forecasts following weak trading and the partial loss of a major client contract.
Traders will be watching out for a potential sharp sell-off approaching at the end of July, as the same period last year saw the worst market turmoil of the year, with several factors pointing to conditions in 2025 being even more ripe for a melt-down.
After the serious market turbulence in the first week of August 2024, Henry Allen, macro strategist at Deutsche Bank, warned that: "This year, that week looks seriously problematic again from a market perspective."